

OXIS International to Present at the Lippert/Heilshorn Life Sciences and Medtech Virtual Conference on February 17

BEVERLY HILLS, Calif., Feb. 14, 2011 -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Paris: OXI) today announced that Anthony Cataldo, Chief Executive Officer, and Bernie Landes, President, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies On-Line Forum on Thursday, February 17, 2011 at 12:30 p.m. Eastern (9:30 a.m. Pacific).

A webcast of the presentation will be accessible online on at the PrecisionIR event site: http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=163285. An archived version will be available for 30 days.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement. Ergothioneine can also be sold to the cosmetics markets as well as the functional food and beverage markets.

SOURCE OXIS International, Inc.

CONTACT: Don Markley, Lippert/Heilshorn & Associates, +1-310-691-7100, dmarkley@lhai.com